WO2015093923A1 - Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes - Google Patents

Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes Download PDF

Info

Publication number
WO2015093923A1
WO2015093923A1 PCT/MX2013/000187 MX2013000187W WO2015093923A1 WO 2015093923 A1 WO2015093923 A1 WO 2015093923A1 MX 2013000187 W MX2013000187 W MX 2013000187W WO 2015093923 A1 WO2015093923 A1 WO 2015093923A1
Authority
WO
WIPO (PCT)
Prior art keywords
administration
mucosa
animal
pharmaceutically acceptable
compositions
Prior art date
Application number
PCT/MX2013/000187
Other languages
Spanish (es)
French (fr)
Inventor
Jorge Isaac CASTRO ALDRETE
José de Jesús MONCADA ZUNO
Original Assignee
Castro Aldrete Jorge Isaac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Castro Aldrete Jorge Isaac filed Critical Castro Aldrete Jorge Isaac
Priority to PCT/MX2013/000187 priority Critical patent/WO2015093923A1/en
Publication of WO2015093923A1 publication Critical patent/WO2015093923A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • intravenous administration can overcome these drawbacks, invasiveness to the animal, difficulties for the owner of the animal, as well as increased costs and risks of infection, make intravenous administration a less viable alternative.
  • a number of mucosal surfaces can be used to deliver pharmaceutical products, including, but not limited to: (i) sublingual surfaces, that is, the mucous membranes that line the floor of the mouth, ( i ⁇ ) the buccal surfaces, that is, the mucous membranes that cover the cheeks, (iii) the lingual surfaces, that is, the membranes of the tongue surface, (iv) the palatine surfaces, that is, the membranes that they cover the roof of the mouth, (v) the surfaces of the pharynx, that is, the membranes of the pharynx, (vi) the gingival mucosa, for example, the gums, and (vii) gingival groove, that is, the cavity formed between teeth and gums
  • Conventional oral administration of a drug through ingestion is often not easily achieved,
  • the oral mucosa offers an attractive route of administration through the administration of systemic drugs to the animals.
  • an oral spray that has a non-toxic aerosol pump can deliver a drug directly into the bloodstream.
  • micro-sized droplets are immediately absorbed through the mucosa in the capillaries, which are located near the surface of the mucosa in the mouth. This process can provide for the definitive absorption of the drug within a short space of time without causing any additional stress for the organs, resulting in the administration of drugs, such as enrofloxacin.
  • enrofloxacin is an antibiotic that falls into the category of fluoroquinolones sold by Bayer Corporation under the trade name Baytril.
  • Enrofloxacin is currently approved by the FDA for the treatment of individual domestic animals and domestic animals in the United States. In September 2005, the FDA withdrew the approval of Baytril for use in water for the treatment of poultry flocks, as this practice was observed to promote the evolution of fluoroquinolone resistant strains of the Campylobacter bacteria, a pathogen human.
  • Fluoroquinolones, such as ciprofloxacin are widely used in the treatment of human disease in the same way.
  • Enrichofloxacin is a bactericidal agent.
  • the bactericidal activity of enrofloxacin is concentration dependent, with cell death susceptible bacteria occurring within 20-30 minutes of exposure.
  • Enrofloxacin It has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.
  • the present invention is directed to compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier.
  • the present invention encompasses new methods of transmucosal administration compositions comprising a therapeutically or prophylactically effective amount of at least one active agent to an animal in need thereof.
  • the compositions of the present invention can be administered to any surface of the mucosa of the animal, preferably an oral mucosa membrane, including lingual surfaces, sublingual surfaces, buccal surfaces, palatine surfaces, and pharyngeal surfaces, preferably Buccal or gingival surfaces.
  • compositions of the present invention can also be administered to more than one membrane of the oral mucosa, for example, lingual and sublingual or lingual, sublingual and buccal surfaces, etc.
  • compositions of the present invention can be administered to the area of the oral cavity of an animal between the teeth and the cheek, thereby allowing the compositions of the present invention to contact at least the oral mucosa and gingival.
  • Transmucosal administration of the compositions of the present invention can be carried out using an aerosol, such as an aerosol or pump spray.
  • at least one active agent is selected from the group consisting of a non-steroidal anti-inflammatory agent, an antiparasitic agent, an antihistamine, a cardiovascular agent, a hormone, an immunosuppressive agent. , a nutraceutical, a vitamin, a mineral, a sedative / tranquilizer / behavior modification agent, an anti-emetic, and an antibiotic, in combination with a pharmaceutically acceptable carrier.
  • the compositions of the present invention are suitable for transmucosal administration, preferably to the oral mucosa and more preferably for administration to the oral mucosa or other surfaces of the oral mucosa.
  • compositions administered transmucosally to the oral mucosa of an animal are easier to administer than, for example, a pill, can decrease the amount of drug needed, and, in turn, decrease adverse effects, while providing Maximum dose response
  • a shorter time frame necessary to achieve maximum plasma concentration and greater bioavailability can be provided by the compositions and methods of the invention.
  • the present invention is carried out by placing suspended enrofloxacin hydrochloride suspended in a saline solution with variable concentration.
  • This material must be free of any contamination before entering the process, which can be done with any conventional process, which will not be included in this invention. Once the material is clean it can be included in a clean container where the pharmaceutical substance to be administered is preserved, it should be mentioned that said substance must be in a liquid state and not contain lumps.
  • the enrofloxacin is then placed in a concentrated pressure vessel so that when the upper part of this vessel is pressed it can be ejected.
  • enrofloxacin has the advantage of having contact with surfaces where there is a bacterial concentration that promotes infection.
  • the formula object of this invention has compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier.

Abstract

The invention relates to a formula that has compositions for transmucosal administration to animals, comprising at least one active agent and a pharmaceutically acceptable vehicle. The active agent is crystallised enrofloxacin which can be applied, by means of the vehicle, via the topical route or via the preferred route. As described in the invention, the topical route by means of transmucosal application is advantageous in that it does not damage any tissues of the animal to which it is being administered.

Description

COMPOSICIONES VETERINARIAS QUE COMPRENDEN UN PRINCIPIO ACTIVO Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE PARA SU ADMINISTRACIÓN A TRAVÉS VETERINARY COMPOSITIONS THAT INCLUDE AN ACTIVE PRINCIPLE AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE FOR ADMINISTRATION THROUGH
DE MUCOSASOF MUCOSAS
ANTECEDENTES BACKGROUND
Es bien conocido que los propietarios de animales y veterinarios igual que la administración oral de un fármaco a un animal tiene sus inconvenientes asociados (por ejemplo, dificultad para tragar, estimulando el animal escupiendo la pildora, o dejar de recibir la dosis adecuada). It is well known that owners of animals and veterinarians, like the oral administration of a drug to an animal, have its associated drawbacks (for example, difficulty swallowing, stimulating the animal by spitting the pill, or stop receiving the proper dose).
Además, la administración oral convencional de fármacos para animales tiene desventajas, como el metabolismo de primer paso hepático y la degradación enzimática en el tracto gastrointestinal, que prohiben la administración de determinados tipos de medicamentos, especialmente los péptidos y proteínas. Aunque la administración intravenosa puede superar estos inconvenientes, la invasividad al animal, las dificultades para el propietario del animal, así como el aumento de los costos y los riesgos de infección, hacen de la administración intravenosa de una alternativa menos viable. In addition, conventional oral administration of drugs for animals has disadvantages, such as hepatic first-pass metabolism and enzymatic degradation in the gastrointestinal tract, which prohibit the administration of certain types of medications, especially peptides and proteins. Although intravenous administration can overcome these drawbacks, invasiveness to the animal, difficulties for the owner of the animal, as well as increased costs and risks of infection, make intravenous administration a less viable alternative.
Por esta razón es importante que los vehículos con los cuales se suministra el medicamento logren retener el principio activo una vez que han ingresado al torrente sanguíneo o al tejido en donde deben de ser liberados. For this reason it is important that the vehicles with which the medicine is supplied manage to retain the active substance once they have entered the bloodstream or the tissue where they must be released.
La absorción transmucosa a través de las superficies de la mucosa oral permite la permeación de los productos farmacéuticos tales como nutrientes o fármacos directamente en el torrente sanguíneo y luego en las células en cuestión de minutos. Dentro de la cavidad oral , un número de superficies de la mucosa puede utilizarse para entregar los productos farmacéuticos , incluyendo, pero no limitado a : ( i ) las superficies sublinguales , es decir , las membranas mucosas que recubren el suelo de la boca , ( i¡ ) las superficies bucales, es decir , la membranas mucosas que recubren las mejillas , ( iii ) las superficies linguales , es decir , las membranas de la superficie de la lengua , (iv ) las superficies palatinas , es decir , las membranas que recubren el techo de la boca , ( v ) las superficies de la faringe , es decir, las membranas de la faringe , ( vi) la mucosa gingival , por ejemplo , las encías , y (vii ) surco gingival , es decir , la cavidad formada entre los dientes y las encías . La administración oral convencional de un fármaco a través de la ingestión a menudo no se logra fácilmente, por diversas razones, tales como la dificultad de que un propietario puede tener en obligar a su animal para tragar un comprimido o líquido, la incapacidad para manejar un animal que no le gusta el sabor de la medicación y se resiste a ser tratados, y condiciones médicas que hacen que sea difícil para los animales toman formulaciones orales. En los animales, estas limitaciones se agravan a menudo porque el animal es consciente de que el tratamiento está destinado a mejorar la condición física del animal. La mucosa oral ofrece una atractiva ruta de administración a través de la administración de fármacos sistémicos a los anímales. Por ejemplo, un spray oral que tiene una bomba de aerosol no tóxico puede administrar un fármaco directamente en el torrente sanguíneo. Cuando se rocía en la boca, las gotitas de tamaño micro se absorben de inmediato a través de la mucosa en los capilares, que se encuentran cerca de la superficie de la mucosa en la boca. Este proceso puede proporcionar para la absorción definitiva de la droga dentro de un corto espacio de tiempo sin causar ningún estrés adicional para los órganos por lo que resulta para la administración de fármacos, como la enrofloxacina. En particular la enrofloxacina es un antibiótico que encaja en la categoría de las fluoroquinolonas vendido por Bayer Corporation bajo el nombre comercial de Baytril. Enrofloxacin está actualmente aprobado por la FDA para el tratamiento de animales domésticos individuales y los animales domésticos en los Estados Unidos. En septiembre de 2005, la FDA retiró la aprobación de Baytril para su uso en agua para el tratamiento de las bandadas de aves de corral, como se observó esta práctica para promover la evolución de cepas resistentes a las fluoroquinolonas de la bacteria Campylobacter, un patógeno humano. Las fluoroquinolonas, como ciprofloxacina son ampliamente utilizados en el tratamiento de la enfermedad humana de igual forma. Transmucosal absorption through the surfaces of the oral mucosa allows the permeation of pharmaceutical products such as nutrients or drugs directly into the bloodstream and then into the cells in a matter of minutes. Within the oral cavity, a number of mucosal surfaces can be used to deliver pharmaceutical products, including, but not limited to: (i) sublingual surfaces, that is, the mucous membranes that line the floor of the mouth, ( i¡) the buccal surfaces, that is, the mucous membranes that cover the cheeks, (iii) the lingual surfaces, that is, the membranes of the tongue surface, (iv) the palatine surfaces, that is, the membranes that they cover the roof of the mouth, (v) the surfaces of the pharynx, that is, the membranes of the pharynx, (vi) the gingival mucosa, for example, the gums, and (vii) gingival groove, that is, the cavity formed between teeth and gums Conventional oral administration of a drug through ingestion is often not easily achieved, for various reasons, such as the difficulty that an owner may have in forcing his animal to swallow a tablet or liquid, the inability to handle a Animal that does not like the taste of medication and resists being treated, and medical conditions that make it difficult for animals to take oral formulations. In animals, these limitations are often aggravated because the animal is aware that the treatment is intended to improve the physical condition of the animal. The oral mucosa offers an attractive route of administration through the administration of systemic drugs to the animals. For example, an oral spray that has a non-toxic aerosol pump can deliver a drug directly into the bloodstream. When sprayed in the mouth, micro-sized droplets are immediately absorbed through the mucosa in the capillaries, which are located near the surface of the mucosa in the mouth. This process can provide for the definitive absorption of the drug within a short space of time without causing any additional stress for the organs, resulting in the administration of drugs, such as enrofloxacin. In particular, enrofloxacin is an antibiotic that falls into the category of fluoroquinolones sold by Bayer Corporation under the trade name Baytril. Enrofloxacin is currently approved by the FDA for the treatment of individual domestic animals and domestic animals in the United States. In September 2005, the FDA withdrew the approval of Baytril for use in water for the treatment of poultry flocks, as this practice was observed to promote the evolution of fluoroquinolone resistant strains of the Campylobacter bacteria, a pathogen human. Fluoroquinolones, such as ciprofloxacin, are widely used in the treatment of human disease in the same way.
La enrofloxacina Es un agente bactericida. La actividad bactericida de enrofloxacina es dependiente de la concentración, con la muerte celular bacterias susceptibles que ocurren dentro de 20-30 minutos de exposición. La enrofloxacina ha demostrado un efecto post-antibiótico significativo para bacterias tanto Gram- negativas y Gram-positivas y es activo en ambas fases estacionarias y de crecimiento de la replicación bacteriana. Enrichofloxacin is a bactericidal agent. The bactericidal activity of enrofloxacin is concentration dependent, with cell death susceptible bacteria occurring within 20-30 minutes of exposure. Enrofloxacin It has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.
DESCRIPCIÓN DE LA TÉCNICA RELACIONADA DESCRIPTION OF THE RELATED TECHNIQUE
En una forma de realización, la presente invención se dirige a composiciones para la administración transmucosa a los animales que comprenden al menos un agente activo y un vehículo farmacéuticamente aceptable. En otra realización, la presente invención abarca nuevos métodos de administración transmucosa composiciones que comprenden una cantidad terapéuticamente o profilácticamente eficaz de al menos un agente activo a un animal en necesidad del mismo. En una forma de realización, las composiciones de la presente invención pueden administrarse a cualquier superficie de la mucosa del animal, preferiblemente una membrana de la mucosa oral, incluyendo superficies linguales, sublinguales superficies, superficies bucales, superficies palatinas, y las superficies faríngeas, preferiblemente bucal o gingival superficies. En otras formas de realización, las composiciones de la presente invención también se pueden administrar a más de una membrana de la mucosa oral, por ejemplo, las superficies linguales y sublinguales o lingual, sublingual y superficies bucales, etc. En aún otras realizaciones , las composiciones de la presente invención se puede administrar a la zona de la cavidad oral de un animal entre los dientes y la mejilla , permitiendo de ese modo las composiciones de la presente invención para ponerse en contacto al menos la mucosa bucal y gingival . In one embodiment, the present invention is directed to compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier. In another embodiment, the present invention encompasses new methods of transmucosal administration compositions comprising a therapeutically or prophylactically effective amount of at least one active agent to an animal in need thereof. In one embodiment, the compositions of the present invention can be administered to any surface of the mucosa of the animal, preferably an oral mucosa membrane, including lingual surfaces, sublingual surfaces, buccal surfaces, palatine surfaces, and pharyngeal surfaces, preferably Buccal or gingival surfaces. In other embodiments, the compositions of the present invention can also be administered to more than one membrane of the oral mucosa, for example, lingual and sublingual or lingual, sublingual and buccal surfaces, etc. In still other embodiments, the compositions of the present invention can be administered to the area of the oral cavity of an animal between the teeth and the cheek, thereby allowing the compositions of the present invention to contact at least the oral mucosa and gingival.
La administración transmucosa de las composiciones de la presente invención puede llevarse a cabo usando un aerosol, tal como un aerosol o pulverizador de bomba. En otra forma de realización de las composiciones de la presente invención , al menos un agente activo se selecciona del grupo que consiste de un agente no esteroide anti-inflamatorio, un agente antiparasitario, un antihistamínico, un agente cardiovascular, una hormona, un agente inmunosupresor, un nutracéutico, una vitamina, un mineral, un agente sedante / tranquilizante / modificación de la conducta, un anti - emético, y un antibiótico, en combinación con un vehículo farmacéuticamente aceptable . Las composiciones de la presente invención son adecuadas para la administración transmucosa, preferiblemente a la mucosa oral y más preferiblemente para la administración a la mucosa bucal u otras superficies de la mucosa oral. Transmucosal administration of the compositions of the present invention can be carried out using an aerosol, such as an aerosol or pump spray. In another embodiment of the compositions of the present invention, at least one active agent is selected from the group consisting of a non-steroidal anti-inflammatory agent, an antiparasitic agent, an antihistamine, a cardiovascular agent, a hormone, an immunosuppressive agent. , a nutraceutical, a vitamin, a mineral, a sedative / tranquilizer / behavior modification agent, an anti-emetic, and an antibiotic, in combination with a pharmaceutically acceptable carrier. The compositions of the present invention are suitable for transmucosal administration, preferably to the oral mucosa and more preferably for administration to the oral mucosa or other surfaces of the oral mucosa.
Los métodos de administración transmucosa de las realizaciones descritas en el presente documento proporciona un método fácil de administrar, seguro y altamente potente para la administración de fármacos a los animales. Las composiciones administradas por vía transmucosa a la mucosa oral de un animal son más fáciles de administrar que , por ejemplo, una pildora , puede disminuir la cantidad de fármaco necesaria, y, a su vez, disminuir los efectos adversos, al tiempo que proporciona la máxima respuesta de dosis . Además, un marco de tiempo más corto necesario para alcanzar la concentración máxima en plasma y mayor biodisponibilidad puede ser proporcionado por las composiciones y métodos de la invención. The methods of transmucosal administration of the embodiments described herein provide an easy to administer, safe and highly potent method for administering drugs to animals. Compositions administered transmucosally to the oral mucosa of an animal are easier to administer than, for example, a pill, can decrease the amount of drug needed, and, in turn, decrease adverse effects, while providing Maximum dose response In addition, a shorter time frame necessary to achieve maximum plasma concentration and greater bioavailability can be provided by the compositions and methods of the invention.
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN DETAILED DESCRIPTION OF THE INVENTION
La presente invención se realiza mediante la colocación de clorhidrato de enrofloxacina molida suspendida en una solución salina con concentración variable. The present invention is carried out by placing suspended enrofloxacin hydrochloride suspended in a saline solution with variable concentration.
Este material debe de estar libre de cualquier contaminación antes de entrar al proceso, misma que puede realizarse con cualquier proceso convencional, que no será incluido en esta invención. Una vez que el material está limpio puede incluirse en un recipiente limpio en donde se conserve la sustancia farmacéutica a administrarse, cabe mencionar que dicha sustancia debe de estar en estado líquido y no contener grumos. This material must be free of any contamination before entering the process, which can be done with any conventional process, which will not be included in this invention. Once the material is clean it can be included in a clean container where the pharmaceutical substance to be administered is preserved, it should be mentioned that said substance must be in a liquid state and not contain lumps.
La enrofloxacina después es colocada en un recipiente de presión concentrada de forma que cuando se presione la parte superior de este recipiente pueda salir expulsada. The enrofloxacin is then placed in a concentrated pressure vessel so that when the upper part of this vessel is pressed it can be ejected.
Así el medicamento puede ser administrado en las superficies mucosas que ya se han descrito anteriormente. Por eso este documento proporciona un método fácil de administrar, seguro y altamente potente para la administración de fármacos a los animales. Thus the medication can be administered on the mucous surfaces that have already been described above. That is why this document provides an easy to administer, safe and highly potent method for administering drugs to animals.
Específicamente la enrofloxacina tiene la ventaja de tener así contacto con superficies en donde exista una concentración bacteriana que promueva la infección. Specifically, enrofloxacin has the advantage of having contact with surfaces where there is a bacterial concentration that promotes infection.
SUMARIO DE LA INVENCIÓN Efectos tangibles en la mejora de la concentración plasmática en cualquier animal mamífero. La fórmula objeto de esta invención tiene composiciones para la administración transmucosa a los animales que comprenden al menos un agente activo y un vehículo farmacéuticamente aceptable. SUMMARY OF THE INVENTION Tangible effects in the improvement of plasma concentration in any mammalian animal. The formula object of this invention has compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier.

Claims

REIVINDICACIONES Habiendo descrito con detalle y amplitud, la invención de mi única y exclusiva propiedad, que considero novedosa, solicito y reclamo como de mi propiedad lo contenido en las siguientes cláusulas: CLAIMS Having described in detail and breadth, the invention of my sole and exclusive property, which I consider novel, I request and claim as my property what is contained in the following clauses:
1. Un método de tratamiento o prevención de una condición en la que comprende un animal no humano: la administración de una composición que comprende al menos un agente activo y un vehículo farmacéuticamente aceptable para la mucosa oral de un animal en necesidad del mismo, proporcionando de este modo la absorción transmucosa de una cantidad farmacéuticamente eficaz del agente activo al sistema circulatorio sistémico del animal. 1. A method of treatment or prevention of a condition in which it comprises a non-human animal: the administration of a composition comprising at least one active agent and a pharmaceutically acceptable carrier for the oral mucosa of an animal in need thereof, providing thus the transmucosal absorption of a pharmaceutically effective amount of the active agent into the systemic circulatory system of the animal.
2. El método de la reivindicación 1, en el que dicha administración comprende la pulverización. 2. The method of claim 1, wherein said administration comprises spraying.
3. El método de la reivindicación 2, en el que dicha pulverización comprende pulverizar sobre la mucosa bucal, la mucosa gingival, mucosa lingual, mucosa palatina , mucosa faríngea, mucosa sublingual, o combinaciones de los mismos del animal no humano. 3. The method of claim 2, wherein said spraying comprises spraying on the oral mucosa, the gingival mucosa, lingual mucosa, palatal mucosa, pharyngeal mucosa, sublingual mucosa, or combinations thereof of the non-human animal.
4. El método de la reivindicación 3, en el que dicha pulverización comprende pulverizar sobre la mucosa bucal. 4. The method of claim 3, wherein said spraying comprises spraying on the oral mucosa.
PCT/MX2013/000187 2013-12-19 2013-12-19 Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes WO2015093923A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000187 WO2015093923A1 (en) 2013-12-19 2013-12-19 Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000187 WO2015093923A1 (en) 2013-12-19 2013-12-19 Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes

Publications (1)

Publication Number Publication Date
WO2015093923A1 true WO2015093923A1 (en) 2015-06-25

Family

ID=53403165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000187 WO2015093923A1 (en) 2013-12-19 2013-12-19 Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes

Country Status (1)

Country Link
WO (1) WO2015093923A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239928A1 (en) * 2005-02-17 2006-10-26 Heit Mark C Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239928A1 (en) * 2005-02-17 2006-10-26 Heit Mark C Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods

Similar Documents

Publication Publication Date Title
Hearnden et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease
ES2787220T3 (en) Liquid-filled capsules
CA2597956C (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20080044455A1 (en) Tonsillitus Treatment
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
US20070248548A1 (en) Stable hydroalcoholic oral spray formulations and methods
CZ156598A3 (en) Use of flurbiprofen for preparing a medicament for treating sore throat
EP3043769B1 (en) Hypertonic antimicrobial therapeutic compositions
DK2387389T3 (en) Composition for oral transmucosal administration of analgesic or antispasmodic molecules
WO2011141685A2 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
BRPI0620403B1 (en) bioadhesive film, dosage unit, method of making a bioadhesive film, and use of a composition
US8722744B2 (en) Galenical form for the administration of paracetamol by transmucous means
ES2459203T3 (en) Combination treatment with drugs
CA3047704A1 (en) Administration of antibiotic compounds for the treatment of streptococcal infections for the treatment of psoriasis
US20180221542A1 (en) Intraluminal therapy system for gastrointestinal infections
ES2684491T3 (en) Technology for drug administration
ES2313281T3 (en) PHARMACEUTICAL COMPOSITION INCLUDING ALCOHOL 2,4-DICLORBENCILICO AND AMILMETACRESOL.
RU2604576C1 (en) Pharmaceutical composition for treating infectious-inflammatory diseases of local application and method of its production and application
ES2742034T3 (en) Pharmaceutical composition containing flurbiprofen
WO2015093923A1 (en) Veterinary compositions comprising an active substance and a pharmaceutically acceptable vehicle for the administration thereof via mucous membranes
RU2604575C1 (en) Pharmaceutical composition for treating infectious-inflammatory diseases of local application and method of its production and application
US9801815B2 (en) Galenical form for the administration of triptans by buccal transmucous means
US20210251886A1 (en) Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
ES2565653T3 (en) Use of betanecol for xerostomia treatment
Agnihotri et al. Novel chewable gum sticks for the treatment of oral candidiasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13899892

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13899892

Country of ref document: EP

Kind code of ref document: A1